Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRV7H0)

Drug Name
Bumetanide Drug Info
Synonyms
Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [1]
Edema MG29 Approved [2]
Therapeutic Class
Diuretics
Cross-matching ID
PubChem CID
2471
ChEBI ID
CHEBI:3213
CAS Number
CAS 28395-03-1
TTD Drug ID
DMRV7H0
VARIDT Drug ID
DR00272
ACDINA Drug ID
D00081

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Solute carrier family 12 member 1 (SLC12A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [14]
Potassium Chloride DMMTAJC Hypokalemia 5C77 Approved [15]
Furosemide DMMQ8ZG Congestive heart failure BD10 Approved [16]
Ethacrynic acid DM60QMR Edema MG29 Approved [17]
Torasemide DMXKJ6C Congestive heart failure BD10 Approved [18]
Bendroflumethiazide DM7EVLC High blood pressure BA00 Approved [19]
Trichlormethiazide DMHAQCO Hypertension BA00-BA04 Approved [20]
Hydroflumethiazide DMVPUQI Congestive heart failure BD10 Approved [19]
Methyclothiazide DMN7SDE Edema MG29 Approved [19]
Chlorthalidone DM4DMBT Edema MG29 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporter 2 (SLC22A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [22]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [6]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [23]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [24]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [25]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [26]
Aciclovir DMYLOVR Genital herpes 1A94 Approved [27]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [28]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [29]
Theophylline DMRJFN9 Bronchitis CA20 Approved [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporter 3 (SLC22A8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [30]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [23]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [24]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [31]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [32]
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [33]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [34]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [35]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [36]
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporter 4 (SLC22A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [38]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [23]
L-Glutamic Acid DM4PUDW Schizophrenia 6A20 Approved [39]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [24]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [40]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [41]
Estrone sulfate DMVBIZL Atrophic vaginitis GA30.2 Approved [42]
Levocetirizine DMQYLGP Allergic rhinitis CA08.0 Approved [43]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [23]
uric acid DMA1MKT Discovery agent N.A. Investigative [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Thiazide-sensitive sodium-chloride cotransporter (SLC12A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metolazone DMB39LO Edema MG29 Approved [45]
Drug(s) Transported By Monocarboxylate transporter 6 (SLC16A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [5]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [5]
Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [46]
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [48]
Paclitaxel DMLB81S Breast carcinoma Approved [6]
Allopurinol DMLPAOB Gout FA25 Approved [6]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [6]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [6]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [28]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [49]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [50]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [51]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [52]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [53]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [54]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [55]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [56]
Epinephrine DM3KJBC Acute asthma CA23 Approved [57]
Chlorthalidone DM4DMBT Edema MG29 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cystic fibrosis transmembrane conductance regulator (CFTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [59]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [60]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [61]
Quercetin DM3NC4M Obesity 5B81 Approved [62]
Miglustat DM5J64S Niemann-Pick disease type C Approved [63]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [64]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [61]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [65]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [65]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class I histocompatibility antigen, alpha chain G (HLA-G)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [67]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [10]
Methotrexate DM2TEOL Anterior urethra cancer Approved [68]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [10]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [69]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [10]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [70]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [10]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [10]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 12 member 2 (SLC12A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [60]
Quercetin DM3NC4M Obesity 5B81 Approved [71]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [72]
Estrone DM5T6US Acne vulgaris ED80 Approved [73]
Ethacrynic acid DM60QMR Edema MG29 Approved [13]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [66]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [74]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [75]
Furosemide DMMQ8ZG Congestive heart failure BD10 Approved [13]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium-dependent phosphate transport protein 4 (SLC17A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [76]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [77]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [78]
AMINOHIPPURIC ACID DMUN54G Discovery agent N.A. Investigative [12]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [79]
uric acid DMA1MKT Discovery agent N.A. Investigative [12]
[3H]estrone-3-sulphate DMGPF0N Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [80]
Quercetin DM3NC4M Obesity 5B81 Approved [81]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [82]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [83]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [84]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [85]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [86]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [87]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [76]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [88]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Blocker [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Thiazide-sensitive sodium-chloride cotransporter (SLC12A3) DT6MDC9 S12A3_HUMAN Substrate [4]
Monocarboxylate transporter 6 (SLC16A5) DT3I124 MOT6_HUMAN Substrate [5]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [6]
Organic anion transporter 4 (SLC22A11) DT06JWZ S22AB_HUMAN Substrate [7]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Regulation of Drug Effects [8]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [9]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Gene/Protein Processing [10]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [11]
Sodium-dependent phosphate transport protein 4 (SLC17A3) OTMJWIBM NPT4_HUMAN Regulation of Drug Effects [12]
Solute carrier family 12 member 2 (SLC12A2) OT3ZJ3LH S12A2_HUMAN Gene/Protein Processing [13]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Regulation of Drug Effects [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4837).
2 Bumetanide FDA Label
3 Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
4 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
5 Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
6 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
7 Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
8 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
9 Effects of a new cystic fibrosis transmembrane conductance regulator inhibitor on Cl- conductance in human sweat ducts. Exp Physiol. 2004 Jul;89(4):417-25. doi: 10.1113/expphysiol.2003.027003. Epub 2004 May 6.
10 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
11 Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. J Clin Pharm Ther. 2006 Apr;31(2):139-47. doi: 10.1111/j.1365-2710.2006.00606.x.
12 Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms. J Pharmacol Sci. 2011;115(2):249-53. doi: 10.1254/jphs.10228sc. Epub 2011 Jan 26.
13 Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877. doi: 10.1038/s41598-018-27995-w.
14 Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
16 Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
17 Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
18 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
19 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
20 Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
21 The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
22 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
23 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
24 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
25 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
26 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
27 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
28 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
29 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
30 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
31 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
32 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
33 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
34 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
35 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
36 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
37 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
38 Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
39 The role of the intracellular glutamate gradient in driving organic anion transporter function.
40 Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
41 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
42 Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505.
43 Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.
44 Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.
45 Inhibition of binding of [3H]metolazone to rat kidney membrane by stilbene disulfonates. Biochem Pharmacol. 1991 Jun 1;41(11):1745-50.
46 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
47 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
48 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
49 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
50 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
51 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
52 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
53 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
54 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
55 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
56 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
57 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
58 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
59 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
60 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
61 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
62 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
63 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
64 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
65 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
66 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
67 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
68 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
69 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
70 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
71 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
72 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
73 Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
74 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
75 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
76 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
77 Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
78 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
79 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
80 Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
81 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
82 ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
83 Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
84 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
85 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
86 Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
87 Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.
88 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.